3-29-2013

Osteoblast-Restricted Disruption of the Growth Hormone Receptor in Mice Results in Sexually Dimorphic Skeletal Phenotypes

Vandana Singhal  
*Johns Hopkins University*

Brian C. Goh  
*Johns Hopkins University*

Mary L. Bouxsein  
*Harvard Medical School*

Marie-Claude Faugere  
*University of Kentucky*, mcfaug0@uky.edu

Douglas J. DiGirolamo  
*Johns Hopkins University*

**Click here to let us know how access to this document benefits you.**

Follow this and additional works at: [https://uknowledge.uky.edu/internalmedicine_facpub](https://uknowledge.uky.edu/internalmedicine_facpub)

Part of the [Medicine and Health Sciences Commons](https://uknowledge.uky.edu/internalmedicine_facpub)

Repository Citation

Singhal, Vandana; Goh, Brian C.; Bouxsein, Mary L.; Faugere, Marie-Claude; and DiGirolamo, Douglas J., "Osteoblast-Restricted Disruption of the Growth Hormone Receptor in Mice Results in Sexually Dimorphic Skeletal Phenotypes" (2013). *Internal Medicine Faculty Publications*. 71.  
[https://uknowledge.uky.edu/internalmedicine_facpub/71](https://uknowledge.uky.edu/internalmedicine_facpub/71)

This Article is brought to you for free and open access by the Internal Medicine at UKnowledge. It has been accepted for inclusion in Internal Medicine Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Osteoblast-Restricted Disruption of the Growth Hormone Receptor in Mice Results in Sexually Dimorphic Skeletal Phenotypes

Notes/Citation Information
Published in Bone Research, v. 1, p. 85-97.

© 2016 Sichuan University

This article is published under a CC BY license (Creative Commons Attribution 4.0 international License). The CC BY License is preferred by many research funding bodies. It allows for maximum dissemination and re-use of open access materials: under this license users are free to share (copy, distribute and transmit) and remix (adapt) the contribution including for commercial purposes, providing they attribute the contribution in the manner specified by the author or licensor (read the full legal code).

Digital Object Identifier (DOI)
http://dx.doi.org/10.4248/BR201301006

This article is available at UKnowledge: https://uknowledge.uky.edu/internalmedicine_facpub/71
Osteoblast-restricted Disruption of the Growth Hormone Receptor in Mice Results in Sexually Dimorphic Skeletal Phenotypes

Vandana Singhal1, Brian C. Goh1, Mary L. Bouxsein2, Marie-Claude Faugere3, Douglas J. DiGirolamo1*

1Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; 3Albert B. Chandler Medical Center, University of Kentucky, Lexington, KY, USA

Growth hormone (GH) exerts profound anabolic actions during postnatal skeletal development, in part, through stimulating the production of insulin-like growth factor-1 (IGF-1) in liver and skeletal tissues. To examine the requirement for the GH receptor (GHR) in osteoblast function in bone, we used Cre-LoxP methods to disrupt the GHR from osteoblasts, both in vitro and in vivo. Disruption of GHR from primary calvarial osteoblasts in vitro abolished GH-induced signaling, as assessed by JAK2/STAT5 phosphorylation, and abrogated GH-induced proliferative and anti-apoptotic actions. Osteoblasts lacking GHR exhibited reduced IGF-1-induced Erk and Akt phosphorylation and attenuated IGF-1-induced proliferation and anti-apoptotic action. In addition, differentiation was modestly impaired in osteoblasts lacking GHR, as demonstrated by reduced alkaline phosphatase staining and calcium deposition. In order to determine the requirement for the GHR in bone in vivo, we generated mice lacking the GHR specifically in osteoblasts (ΔGHR), which were born at the expected Mendelian frequency, had a normal life span and were of normal size. Three week-old, female ΔGHR mice had significantly reduced osteoblast numbers, consistent with the in vitro data. By six weeks of age however, female ΔGHR mice demonstrated a marked increase in osteoblasts, although mineralization was impaired; a phenotype similar to that observed previously in mice lacking IGF-1R specifically in osteoblasts. The most striking phenotype occurred in male mice however, where disruption of the GHR from osteoblasts resulted in a “feminization” of bone geometry in 16 week-old mice, as observed by μCT. These results demonstrate that the GHR is required for normal postnatal bone development in both sexes. GH appears to serve a primary function in modulating local IGF-1 action. However, the changes in bone geometry observed in male ΔGHR mice suggest that, in addition to facilitating IGF-1 action, GH may function to a greater extent than previously appreciated in establishing the sexual dimorphism of the skeleton.

Keywords: growth hormone; osteoblasts; knockout mice; bone; sexual dimorphism


Introduction

Bone acquisition and remodeling depend on the coordinated activities of bone-forming osteoblasts and bone-resorbing osteoclasts. During postnatal development, the activity and lifespan of osteoblasts is regulated by many local growth factors, cytokines, and systemic hormones (1,2). Among these, growth hormone (GH) and insulin-like growth factor-1 (IGF-1) exert anabolic activity, particularly during the rapid phases of bone acquisition that occur during the pubertal growth
sput. GH is a cytokine peptide (3) produced and stored by somatotroph cells of the anterior pituitary. GH functions by binding to its homodimeric transmembrane GH receptor (GHR) and triggering conformational changes (4) that lead to activation of associated JAKs (5-7) to activate STATs (8-16), PI3K/Akt (17, 18) and ERK (19-21). GH-induced activation of STAT5b results in transcriptional activation of IGF-1 (20, 22-24).

In many tissues, GH actions are mediated by its ability to stimulate the production of IGF-1, a widely expressed polypeptide that bears homology to pro-insulin. IGF-1 signals primarily via the heterotetrameric type-1 IGF-1 receptor (IGF-1R) to trigger ERK and PI3K/Akt activation via SHC and insulin receptor substrate-1 and -2 (IRS-1/2) (25,26). IGF-1 is an important growth and survival factor for many cell types, including osteoblasts (27,28). IGF-1 also plays a role in differentiation of fetal rat calvarial osteoblasts to augment type I collagen synthesis and inhibit collagen degradation (29). The role of IGF-1 in bone is well established. For example, osteoblast-specific over-expression of IGF-1 in mice accelerates new bone formation and also increases the rate at which matrix is mineralized (30). Conversely, osteoblast-specific disruption of the IGF-1R results in markedly impaired mineralization of trabecular bone (31).

The precise role of GH in bone has been difficult to define due to the intimate linkage between GH and IGF-1 production. High affinity GH receptors are expressed in osteoblast-like cell lines (32, 33) and in primary mouse osteoblasts (34-36). In addition, GH has been shown to stimulate proliferation of cultured osteoblasts (33). Mice globally deficient in either IGF-1 or GH have impaired postnatal bone acquisition, with the defect being more severe in the IGF-1-nulls (37), suggesting that GH might exert actions independent of IGF-1 in bone. Moreover, treatment of IGF-1 null mice with GH significantly increases mineral apposition and bone formation rates (38). However, interpretation of these models is confounded by the overall growth retardation seen in these mice, as well as problems with reproductive hormone status.

To overcome some of these potentially confounding problems, we used a Cre-LoxP strategy to create a mouse lacking GHR specifically in osteoblasts, which enabled us to determine the requirement of GHR for osteoblast function, both in vitro and in vivo. Our results demonstrate that the GHR is required for normal postnatal bone development in both sexes. As may be expected, GH appears to serve a primary function in modulating local IGF-1 action. Interestingly, osteoblast-restricted disruption of the GHR in male mice resulted in “feminization” of bone geometry in adult animals, suggesting GH may function to a greater extent than previously appreciated in establishing the sexual dimorphism of the skeleton.

Methods

Materials

Cell culture media, α-minimal essential medium (αMEM), was obtained from Cellgro-Mediatech (Herdon, VA) and fetal bovine serum (FBS) was from Gibco (Gaithersburg, MD). Bovine GH was obtained from the National Hormone and Peptide Program-Monsanto (Torrance, CA) and stored in 200X aliquots for single use. Human IGF-1 was obtained from GroPep (Theberton, SA, Australia) and stored in 1000X aliquots for single use. Antibodies used for immunoblotting included anti-β-actin (C4) from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); anti-phospho-JAK2 (Tyr1007/1008), anti-JAK2, anti-phospho-STAT5 (Tyr 694), anti-STAT5, anti-phospho-Akt (Ser 473), anti-Akt, anti-phospho-ERK (Thr202/Tyr204), anti-ERK, anti-IGF-1R from Cell Signaling Technology (Danvers, MA), and anti-GHR AL47(a generous gift from Dr. Stuart Frank, University of Alabama at Birmingham, Birmingham, AL). Horseradish-peroxidase conjugated rabbit and mouse secondary antibodies were obtained from Pierce Biotechnology, Rockford, IL. Polyvinylidene difluoride (PVDF) membrane, Laemmli sample buffer and other electrophoresis supplies were from Bio-Rad. Assay kits for flow cytometry analysis of cell proliferation were purchased from BD Pharmingen (San Jose, CA). All other reagents not specified here were purchased from Sigma.

Osteoblast isolation and culture

Osteoblasts were isolated from calvaria of newborn GHRfloxed mice by serial digestion in 1.8 mg·mL−1 collagenase type I (Worthington, Lakewood, NJ) solution. Calvaria were digested in 10 mL of digestion solution for 15 min at 37 °C with constant agitation. The digestion solution was collected, and digestion was repeated with fresh digestion solution an additional four times. Digestions 3–5 (containing the osteoblasts) were pooled together, centrifuged, washed with αMEM containing 10% FBS, 1% pen/strep, and plated overnight at 37 °C in a humidified incubator supplied with 5% CO2. For in vitro deletion of the GHR, GHR floxed osteoblasts were cultured to be 70% confluent and then, in the absence of serum, were infected with adenovirus encoding Cre recombinase (Ad-Cre) (Vector Biolabs, Philadelphia, PA) at a titer of 100 multiplicity of infection (moi). Infection with 100 moi of adenovirus encoding green fluorescent protein (Ad-GFP) (Vector Biolabs) was used as control. After 1 hour, culture medium containing 10% FBS was
added and the cells were allowed to recover for the next 48 h. Greater than 90% GHR deletion was confirmed for every infection by quantitative real-time PCR analysis and immunoblotting. For differentiation, osteoblasts were grown to confluence and then switched to differentiation media supplemented with β-glycerophosphate and ascorbic acid for 7 days prior to alkaline phosphatase staining or 14 days prior to alizarin red S staining by standard methods.

Cell lysis and immunoblotting analysis
For signaling experiments, osteoblasts were cultured in αMEM containing 10% FBS until 90% confluent, and then serum starved in αMEM containing 0.1% FBS for 24 hours to reduce cellular activity to quiescent levels prior to stimulation. At the end of the study, the cells were washed twice with ice-cold phosphate-buffered saline (PBS) and resuspended in lysis buffer (50 mmol·L⁻¹ Tris (pH 7.4), 150 mmol·L⁻¹ NaCl, 1 mmol·L⁻¹ MgCl₂, 1 mmol·L⁻¹ EDTA, 1% Triton X-100, and 10% glycerol). Protease and phosphatase inhibitors (Sigma) were added to the lysis buffer. The cell lysates were homogenized by needle aspiration and protein concentration was measured by Bradford protein assay (Bio-Rad). For immunoblotting of whole cell lysates, equal amounts of protein (10 or 20 µg per lane) were solubilized in Laemmli sample buffer and loaded onto a mini-SDS-PAGE system. Following electrophoresis, proteins were transferred to a PVDF membrane using a Bio-Rad semi-dry transfer system. Protein transfer efficiency was verified using pre-stained protein markers. Membranes were then blocked with 5% non-fat dry milk for 1 hour at room temperature and subsequently incubated overnight at 4 °C with antibodies directed against the protein of interest. Signals were detected using a horseradish peroxidase-conjugated secondary antibody and bound antibodies were visualized using the Supersignal West Femto Substrate (Pierce). Western blot photographic results were scanned with a Canon flatbed scanner.

Quantitative real-time PCR
Total RNA was extracted from cells using the TRizol® method, as recommended by the manufacturer (Invitrogen). The RNA concentration was estimated spectrophotometrically and only pure RNA (A260:A280 ratio ≥ 1.8) was used for further analysis. First strand cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad). The cDNA was amplified in the Opticon Continuous Fluorescent Detector (MJ Research, Waltham, MA) using IQ™ SYBR Green supermix (Bio-Rad) and sequence specific primers. PCR reactions were performed in triplicate for each cDNA, averaged, and normalized to endogenous β-actin reference transcripts. Primer sequences used were as follows: GHR: 5’-GATTITACC-CCAGTCCAGTCC-3’, 5’-GACCCTAGCTCTICCTA-TCCAC-3’; β-actin: 5’-ACCTTCCTCAATAGCTGCT-3’, 5’-TGCCAATAGTGATGACCT-3’.

Osteoblast proliferation assays
Osteoblasts were plated in 6-well plates at low cell density (9 x 10⁴ cells per well) and cultured in αMEM containing 1% FBS for 24 hours to arrest the cells in G₀ phase. The cells were then stimulated with 500 ng·mL⁻¹ GH or 100 ng·mL⁻¹ IGF-1 for 48 hours. For proliferation analysis of the cells, 10 µmol·L⁻¹ BrdU was added to the medium at the time of mitogenic stimulation. The cells were then stained with anti-BrdU-APC and 7-AAD and analyzed by FAC5 Calibur (Becton-Dickson). 20,000 events were collected for each sample and results were analyzed with WinMDI version 2.8.

Osteoblast apoptosis assays
Osteoblasts were plated at confluence in 96 well plates in 1% FBS containing media. They were then pretreated for 24 hours with GH or IGF-1 before induction of apoptosis (8 ng·mL⁻¹ staurosporine). Apoptosis was assessed by Promega CaspaseGlo 3/7 according to manufacturer's instructions after 8 hours.

Animal studies
Osteoblast-restricted disruption of the GHR was achieved by crossing mice carrying floxed GHR alleles (GHR²/²) (39) with mice expressing the Cre recombinase under the control of the human osteocalcin promoter (OC-Cre) (31). Recombination was confirmed in skeletal tissues by allele specific PCR using a forward primer upstream of the floxed exon 4 of GHR, in combination with two reverse primers-one within the floxed exon 4 that resulted in ~720 bp product and one downstream of exon 4 that resulted in ~1300 bp product following recombination. Male and female control (GHR²/²) and ΔGHR (GHR²/² OC-Cre²) mice were sacrificed at 3, 6, and 16 weeks of age and femurs were removed and fixed in 100% ethanol. Prior to sacrifice, 3- and 6-week-old mice were administered intraperitoneal injections of 100 µL of a 1% calcin solution (to assess dynamic histomorphometric parameters) on a split dose schedule leaving 3 days (for 3-week-old animals) or 5 days (for 6-week-old animals) between the first and second dose, and 2 days (3-week-old) or 3 days (6-week-old) following the second dose before sacrifice. Micro-computed tomography analysis (µCT) of the femur was performed at the Orthopedic Biomechanics Laboratory at Beth Israel Deaconess Medical Center (Boston, MA) and at the
Center for Musculoskeletal Research at Johns Hopkins University. For histomorphometric analysis, femurs were embedded and sectioned. Five serial sections were stained using the Masson-Goldner trichrome technique, and five more serial sections were left unstained for fluorescent microscopy. Static and dynamic parameters of bone structure and formation were measured at the Albert B. Chandler Medical Center at the University of Kentucky (Lexington, KY).

Statistical analysis
All statistical analyses were performed using the Microsoft Excel data analysis program for ANOVA or Student’s t-test analysis with an assigned significance level of 0.05 (α). All experiments were repeated at least three times unless otherwise stated. Values are expressed as a mean±S.E.M.

Results
Disruption of GHR in osteoblasts in vitro abolishes GH signaling and attenuates IGF-1 activity
To examine the requirement of GHR for osteoblast function in vitro, primary osteoblasts from mice carrying homozygous floxed GHR alleles were infected with Cre-expressing adenovirus constructs (AdCre) or adenovirus expressing GFP as a control (GFP). Real time PCR analysis of GHR mRNA expression (Figure 1A) showed a 90% reduction in GHR mRNA in osteoblasts infected with 100 moi of AdCre and a complete loss of GHR protein (Figure 1B). Importantly, IGF-1R protein levels were unaffected in AdCre cells (Figure 1B), and infection of wild-type (non-floxed) osteoblasts with AdCre had no discernable effects on basal, GH- or IGF-1-induced ERK or Akt phosphorylation (not shown). GH-induced JAK2, STAT5 and ERK phosphorylation were completely abolished (Figure 1C) following GHR disruption.

Previous studies have described a functional independence between GHR and IGF-1R, such that the presence of both receptors is required for each receptor to exert its full competency (40). We therefore examined IGF-1-induced signals in osteoblasts following disruption of GHR. IGF-1-induced ERK activation was blunted in AdCre osteoblasts compared to GFP osteoblasts, and Akt phosphorylation was also reduced (Figure 1C). These results suggest that, in accord with previous observations, GHR is required for full potency of IGF-1R signaling.

Disruption of GHR reduces the proliferative and anti-apoptotic effects of IGF-1
To assess the effect of the GHR on osteoblast proliferation, GFP and AdCre osteoblasts were serum starved for 24 hours and then treated with vehicle, GH or IGF-1. BrdU incorporation, indexed at 48 hours by flow cytometry, showed that both GH and IGF-1 significantly induced BrdU uptake in GFP control cells (Figure 2A). Disruption of GHR abolished GH-induced BrdU uptake and blunted IGF-1-induced BrdU uptake as well (Figure 2A), consistent with the attenuation of IGF-1 signaling observed in the AdCre osteoblasts above (Figure 1C). To determine the requirement of the GHR for osteoblast survival, GFP and AdCre osteoblasts were pre-treated with vehicle, GH or IGF-1 in 1% serum containing media, and then exposed to staurosporine to induce apoptosis. In GFP control osteoblasts, both GH and IGF-1 significantly attenuated staurosporine-induced apoptosis as measured by caspase 3/7 activation (Figure 2B). As expected, disruption of GHR abolished the anti-apoptotic activity of GH (Figure 2B). Moreover, the ability of IGF-1 to attenuate staurosporine-induced apoptosis was also eliminated in ΔGHR osteoblasts (Figure 2B).

Disruption of GHR impairs osteoblast differentiation in vitro
To then assess the effect of GHR signaling on osteoblast differentiation in vitro, GFP and AdCre osteoblasts were grown to confluence and before being switched to differentiation media supplemented with β-glycerophosphate and ascorbic acid. AdCre osteoblasts demonstrated a modest, but consistent, reduction in alkaline phosphatase staining at seven days of culture (Figure 2C) and calcium deposition at 14 days of culture (Figure 2D). Taken together, these in vitro data suggest that the GHR is required for normal osteoblast function, and further, that loss of the GHR appears to blunt IGF-1R function in osteoblasts.

Osteoblast-restricted disruption of GHR in vivo
To determine the requirement of the GHR for osteoblast function in vivo, we conditionally disrupted the GHR in osteoblasts (ΔGHR mice) by crossing GHR floxed mice (GHRfl/fl) with mice that express the Cre recombinase under the control of the human osteocalcin promoter (OC-Cre). ΔGHR mice were born at the expected Mendelian frequency, had a normal life span, and exhibited no differences in body weight or length compared to control littermates (not shown). Allele-specific PCR, to identify both the floxed and recombined GHR alleles, demonstrated that recombination occurred only in bone tissues of ΔGHR mice (Figure 3A). μCT measurements were performed at 3, 6 and 16 weeks of age in, both male and female, control and ΔGHR mice. Representative cross-section images of trabecular bone at the distal femur (left) and cortical bone at the femoral
Figure 1 Cre-mediated excision of GHR from primary mouse osteoblasts abolishes GH signaling and attenuates IGF-1 signaling. Calvarial osteoblasts isolated from newborn mice carrying floxed GHR alleles were infected with AdGFP as control or AdCre for deletion. After two days in culture, GHR mRNA expression was assessed by real-time PCR (A), and protein levels of GHR and IGF-1R were analyzed by immunoblotting (B). GFP or AdCre osteoblasts were grown to confluence and serum starved for 24 hours before stimulation with vehicle, GH or IGF-1 for 10 minutes. Cells were lysed and cell lysates immunoblotted with anti-phospho-JAK2 (arrow) and anti-JAK2, anti-phospho-STAT5 and anti-STAT5, anti-phospho-ERK and anti-ERK, or anti-phospho-Akt and anti-Akt (C). Graphs represent densitometric analysis of three experiments. *p<0.05
midshaft (right) are shown (Figure 3B-Female, Figure 3C-Male). Complete μCT data for all groups can be found in Table 1. Histomorphometric analysis was performed on the contralateral femur of these same animals, and complete morphometric data are listed in Table 2.

In female ΔGHR mice, μCT analysis revealed only modest changes throughout postnatal development, including a slight increase in cortical thickness and cross-sectional area at three weeks of age and slight cortical thinning at six weeks of age, when compared to controls (Figure 3B and Table 1). However, histomorphometric analysis of trabecular bone in the distal femur revealed a phenotype strikingly similar to that previously observed in female mice with osteoblast-restricted disruption of the IGF-1R (31). At three weeks of age, female ΔGHR mice had less than half the numbers of osteoblasts seen in control mice (Figure 4A). The reduction in osteoblasts in female ΔGHR mice reversed by six weeks of age, such that female ΔGHR mice increased to twice the number of osteoblasts seen in control animals at six weeks (Figure 4B)—again, similar to previous observations in female mice lacking IGF-1R in osteoblasts at six weeks of age. Consistent with the in vitro differentiation results, osteoblasts in six-week-old female ΔGHR mice appeared to be functionally impaired, as indicated by reduced bone formation rate per osteoblast and a trend toward increased mineralization lag time (Figure 4C and 4D).

In contrast to female mice, male ΔGHR mice with osteoblast-restricted disruption of the GHR exhibited a skeletal phenotype with age that could be easily appreciated by μCT analysis (Figure 3C and Table 1). While there were no significant changes observed by μCT at earlier ages, 16-week-old male ΔGHR mice had significantly smaller bones than control animals that appeared remarkably similar to bones from female animals, with reduced trabecular bone volume and significantly smaller medullary area (Figure 5A and 5B). Although no differences were observed in osteoblast numbers between control and ΔGHR mice at 16 weeks of age, the reduction in osteoblasts in male ΔGHR mice reversed by 16 weeks of age, such that male ΔGHR mice increased to twice the number of osteoblasts seen in control animals at 16 weeks of age. Consistent with the in vitro differentiation results, osteoblasts in six-week-old male ΔGHR mice appeared to be functionally impaired, as indicated by reduced bone formation rate per osteoblast and a trend toward increased mineralization lag time (Figure 4C and 4D).
Table 1 μCT analysis

<table>
<thead>
<tr>
<th></th>
<th>Female Control</th>
<th>3 weeks (n=5)</th>
<th>6 weeks (n=6)</th>
<th>16 weeks (n=5)</th>
<th>ΔGHR Control</th>
<th>3 weeks (n=6)</th>
<th>6 weeks (n=5)</th>
<th>16 weeks (n=7)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Female</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Trabecular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BV/TV (%)</td>
<td>13.16 ± 1.07</td>
<td>14.99 ± 1.70</td>
<td>14.80 ± 1.64</td>
<td>15.71 ± 1.35</td>
<td>14.95 ± 1.00</td>
<td>13.33 ± 1.71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.N (mm⁻¹)</td>
<td>4.83 ± 0.24</td>
<td>4.30 ± 0.30</td>
<td>4.33 ± 0.17</td>
<td>5.80 ± 0.40</td>
<td>4.61 ± 0.18</td>
<td>4.19 ± 0.27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.Th (mm)</td>
<td>38.57 ± 0.52</td>
<td>49.57 ± 0.50</td>
<td>53.60 ± 1.10</td>
<td>39.32 ± 0.70</td>
<td>48.42 ± 0.44</td>
<td>51.96 ± 0.87</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.Sp (mm)</td>
<td>224.33 ± 9.35</td>
<td>239.63 ± 16.85</td>
<td>228.48 ± 10.49</td>
<td>190.38 ± 14.91</td>
<td>216.98 ± 8.30</td>
<td>239.94 ± 18.09</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cortical</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT.Th (mm)</td>
<td>89.67 ± 5.24</td>
<td>148.17 ± 4.74</td>
<td>190.80 ± 4.49</td>
<td>101.63 ± 3.15a</td>
<td>136.80 ± 2.82a</td>
<td>192.14 ± 6.41</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.N (mm⁻¹)</td>
<td>3.20 ± 0.03</td>
<td>0.59 ± 0.03</td>
<td>0.71 ± 0.03</td>
<td>0.34 ± 0.02</td>
<td>0.54 ± 0.03</td>
<td>0.72 ± 0.03</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.Th (mm)</td>
<td>38.57 ± 0.52</td>
<td>49.57 ± 0.50</td>
<td>53.60 ± 1.10</td>
<td>39.32 ± 0.70</td>
<td>48.42 ± 0.44</td>
<td>51.96 ± 0.87</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.Sp (mm)</td>
<td>224.33 ± 9.35</td>
<td>239.63 ± 16.85</td>
<td>228.48 ± 10.49</td>
<td>190.38 ± 14.91</td>
<td>216.98 ± 8.30</td>
<td>239.94 ± 18.09</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Male</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Trabecular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BV/TV (%)</td>
<td>12.88 ± 0.82</td>
<td>22.39 ± 1.28</td>
<td>14.28 ± 1.08</td>
<td>13.95 ± 0.97</td>
<td>23.37 ± 2.01</td>
<td>9.73 ± 0.60a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.N (mm⁻¹)</td>
<td>5.21 ± 0.41</td>
<td>6.05 ± 0.22</td>
<td>4.76 ± 0.14</td>
<td>5.00 ± 0.10</td>
<td>6.00 ± 0.25</td>
<td>4.14 ± 1.04a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.Th (mm)</td>
<td>38.92 ± 0.52</td>
<td>50.56 ± 1.96</td>
<td>50.80 ± 0.74</td>
<td>39.10 ± 0.80</td>
<td>52.09 ± 3.33</td>
<td>49.75 ± 1.87</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.Sp (mm)</td>
<td>211.88 ± 19.21</td>
<td>161.16 ± 6.83</td>
<td>207.78 ± 6.43</td>
<td>214.77 ± 4.45a</td>
<td>164.48 ± 9.05</td>
<td>238.78 ± 5.78a</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cortical</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT.Ar (mm²)</td>
<td>98.80 ± 3.07</td>
<td>154.80 ± 4.35</td>
<td>209.00 ± 4.23</td>
<td>97.67 ± 1.86</td>
<td>163.25 ± 3.29</td>
<td>206.43 ± 5.70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.N (mm⁻¹)</td>
<td>0.34 ± 0.02</td>
<td>0.65 ± 0.05</td>
<td>0.88 ± 0.01</td>
<td>0.36 ± 0.03</td>
<td>0.70 ± 0.04</td>
<td>0.83 ± 0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.Th (mm)</td>
<td>98.80 ± 3.07</td>
<td>154.80 ± 4.35</td>
<td>209.00 ± 4.23</td>
<td>97.67 ± 1.86</td>
<td>163.25 ± 3.29</td>
<td>206.43 ± 5.70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.Sp (mm)</td>
<td>211.88 ± 19.21</td>
<td>161.16 ± 6.83</td>
<td>207.78 ± 6.43</td>
<td>214.77 ± 4.45a</td>
<td>164.48 ± 9.05</td>
<td>238.78 ± 5.78a</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Trabecular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BV/TV (%)</td>
<td>13.16 ± 1.07</td>
<td>14.99 ± 1.70</td>
<td>14.80 ± 1.64</td>
<td>15.71 ± 1.35</td>
<td>14.95 ± 1.00</td>
<td>13.33 ± 1.71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.N (mm⁻¹)</td>
<td>4.83 ± 0.24</td>
<td>4.30 ± 0.30</td>
<td>4.33 ± 0.17</td>
<td>5.80 ± 0.40</td>
<td>4.61 ± 0.18</td>
<td>4.19 ± 0.27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.Th (mm)</td>
<td>38.57 ± 0.52</td>
<td>49.57 ± 0.50</td>
<td>53.60 ± 1.10</td>
<td>39.32 ± 0.70</td>
<td>48.42 ± 0.44</td>
<td>51.96 ± 0.87</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.Sp (mm)</td>
<td>224.33 ± 9.35</td>
<td>239.63 ± 16.85</td>
<td>228.48 ± 10.49</td>
<td>190.38 ± 14.91</td>
<td>216.98 ± 8.30</td>
<td>239.94 ± 18.09</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cortical</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT.Ar (mm²)</td>
<td>98.80 ± 3.07</td>
<td>154.80 ± 4.35</td>
<td>209.00 ± 4.23</td>
<td>97.67 ± 1.86</td>
<td>163.25 ± 3.29</td>
<td>206.43 ± 5.70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.N (mm⁻¹)</td>
<td>0.34 ± 0.02</td>
<td>0.65 ± 0.05</td>
<td>0.88 ± 0.01</td>
<td>0.36 ± 0.03</td>
<td>0.70 ± 0.04</td>
<td>0.83 ± 0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.Th (mm)</td>
<td>38.57 ± 0.52</td>
<td>49.57 ± 0.50</td>
<td>53.60 ± 1.10</td>
<td>39.32 ± 0.70</td>
<td>48.42 ± 0.44</td>
<td>51.96 ± 0.87</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.Sp (mm)</td>
<td>224.33 ± 9.35</td>
<td>239.63 ± 16.85</td>
<td>228.48 ± 10.49</td>
<td>190.38 ± 14.91</td>
<td>216.98 ± 8.30</td>
<td>239.94 ± 18.09</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Trabecular parameters were assessed at the distal femur and cortical parameters at the femoral midshaft; BV/TV–bone volume fraction; Tb.N–trabecular number; Tb.Th–trabecular thickness; Tb.Sp–trabecular separation; Ct.Th–average cortical thickness; Ct.Ar–cortical bone area; Tt.Ar–total cross-sectional area (inside periosteal envelope); Ma.Ar–medullary area; Ct.Ar/Tt.Ar–cortical area fraction. Values shown are mean±SEM.

*P*<0.05 vs. age-matched control

---

Figure 3 Osteoblast-specific disruption of the GHR in vivo results in sexually dimorphic skeletal changes. Allele-specific PCR confirms recombination occurs only in skeletal tissues of ΔGHR mice (A). Representative μCT images of cross sections of trabecular bone in the distal femur (left) and cortical bone in the femoral midshaft (right) from control and ΔGHR mice at the indicated ages are shown for female (B) and male (C) mice.
Histomorphometry was performed in trabecular bone of the distal femur. BV/TV—Bone volume/tissue volume; Tb.Th—Trabecular thickness; Tb.Sp—Trabecular separation; OV/BV—Osteoid volume/bone volume; O.S/B—Osteoid surface/bone surface; O.Th—Osteoid thickness; Ob.S/Bs—Osteoblast surface/bone surface; N.Ob/B.Pm—Osteoblast number/bone perimeter; MAR—Mineral apposition rate; BFR/BS—Bone formation rate/bone surface; MS/BS—Mineralizing surface/bone surface; N.Oc/B.Pm—Osteoclast number/bone perimeter; W.R—Whole body weight ratio; Mlt—Mineralization lag time; BFR/N.Ob—Bone formation rate/osteoblast; E.De—Erosion depth; ER—Erosion rate; ES—Erosion surface; Et-Ex—Early/late phase; Et—Early phase; Ex—Late phase.

Values shown are mean±S.E.M.

Table 2 Bone histomorphometry

<table>
<thead>
<tr>
<th></th>
<th>Female</th>
<th>Control</th>
<th>ΔGHR</th>
<th></th>
<th>Female</th>
<th>Control</th>
<th>ΔGHR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3 weeks (n=5)</td>
<td>6 weeks (n=6)</td>
<td>16 weeks (n=5)</td>
<td>3 weeks (n=6)</td>
<td>6 weeks (n=8)</td>
<td>16 weeks (n=5)</td>
<td></td>
</tr>
<tr>
<td>Bone BV/TV (%)</td>
<td>5.28 ± 0.79</td>
<td>8.14 ± 1.53</td>
<td>10.86 ± 1.87</td>
<td>7.48 ± 0.64a</td>
<td>8.21 ± 0.83</td>
<td>8.06 ± 1.00a</td>
<td></td>
</tr>
<tr>
<td>Bone Tb.Th (mm)</td>
<td>14.68 ± 0.41</td>
<td>18.37 ± 0.51</td>
<td>20.93 ± 0.87</td>
<td>19.24 ± 1.34</td>
<td>22.59 ± 1.27</td>
<td>23.55 ± 1.47</td>
<td></td>
</tr>
<tr>
<td>Bone Tb.Sp (mm)</td>
<td>305.20 ± 13.10</td>
<td>272.39 ± 21.14</td>
<td>230.98 ± 26.05</td>
<td>246.02 ± 26.64a</td>
<td>270.09 ± 29.11</td>
<td>303.93 ± 55.05</td>
<td></td>
</tr>
<tr>
<td>Bone O.S/Bs (%)</td>
<td>3.24 ± 0.38</td>
<td>6.25 ± 0.95</td>
<td>6.59 ± 0.65</td>
<td>3.63 ± 0.78</td>
<td>6.25 ± 0.95</td>
<td>5.96 ± 0.41a</td>
<td></td>
</tr>
<tr>
<td>Bone N.Ob/B.Pm</td>
<td>15.41 ± 2.48</td>
<td>15.41 ± 2.48</td>
<td>15.06 ± 2.48</td>
<td>11.71 ± 1.67</td>
<td>13.33 ± 2.52</td>
<td>13.33 ± 2.52</td>
<td></td>
</tr>
<tr>
<td>Bone O.Th (mm)</td>
<td>0.9 ± 0.13</td>
<td>1.7 ± 0.27</td>
<td>2.94 ± 0.27</td>
<td>2.26 ± 0.18</td>
<td>2.47 ± 0.33</td>
<td>2.29 ± 0.36</td>
<td></td>
</tr>
<tr>
<td>Bone Ob.S/Bs (%)</td>
<td>9.20 ± 3.00</td>
<td>7.18 ± 4.85</td>
<td>2.80 ± 1.30</td>
<td>11.77 ± 0.52</td>
<td>10.39 ± 2.02</td>
<td>2.00 ± 0.58</td>
<td></td>
</tr>
<tr>
<td>Bone N.Ob/B.Pm (no/100mm)</td>
<td>1216.61 ± 248.42</td>
<td>567.28 ± 325.23</td>
<td>263.12 ± 106.59</td>
<td>1735.86 ± 119.14a</td>
<td>1016.92 ± 207.13</td>
<td>671.0 ± 1.01</td>
<td></td>
</tr>
<tr>
<td>Bone BV/TV (%)</td>
<td>7.93 ± 1.75</td>
<td>7.00 ± 1.04</td>
<td>7.97 ± 2.94</td>
<td>7.33 ± 1.64</td>
<td>10.97 ± 1.59a</td>
<td>6.71 ± 1.01</td>
<td></td>
</tr>
<tr>
<td>Bone Tb.Th (mm)</td>
<td>17.16 ± 1.69</td>
<td>23.12 ± 1.15</td>
<td>24.57 ± 2.40</td>
<td>15.90 ± 3.01</td>
<td>26.77 ± 1.99</td>
<td>21.17 ± 1.08</td>
<td></td>
</tr>
<tr>
<td>Bone Tb.Sp (mm)</td>
<td>204.27 ± 15.89</td>
<td>233.33 ± 51.57</td>
<td>484.96 ± 137.20</td>
<td>204.27 ± 15.89</td>
<td>242.38 ± 30.04a</td>
<td>306.35 ± 28.09</td>
<td></td>
</tr>
<tr>
<td>Bone O.S/Bs (%)</td>
<td>2.92 ± 0.74</td>
<td>6.70 ± 2.16</td>
<td>22.02 ± 6.22</td>
<td>13.53 ± 2.42</td>
<td>10.97 ± 2.52</td>
<td>23.36 ± 6.22</td>
<td></td>
</tr>
<tr>
<td>Bone N.Ob/B.Pm (no/100mm)</td>
<td>1.13 ± 0.14</td>
<td>2.05 ± 0.27</td>
<td>2.94 ± 0.27</td>
<td>2.26 ± 0.18</td>
<td>2.47 ± 0.33</td>
<td>2.29 ± 0.36</td>
<td></td>
</tr>
<tr>
<td>Bone BV/TV (%)</td>
<td>7.93 ± 1.75</td>
<td>7.00 ± 1.04</td>
<td>7.97 ± 2.94</td>
<td>7.33 ± 1.64</td>
<td>10.97 ± 1.59a</td>
<td>6.71 ± 1.01</td>
<td></td>
</tr>
<tr>
<td>Bone Tb.Th (mm)</td>
<td>17.16 ± 1.69</td>
<td>23.12 ± 1.15</td>
<td>24.57 ± 2.40</td>
<td>15.90 ± 3.01</td>
<td>26.77 ± 1.99</td>
<td>21.17 ± 1.08</td>
<td></td>
</tr>
<tr>
<td>Bone Tb.Sp (mm)</td>
<td>204.27 ± 15.89</td>
<td>233.33 ± 51.57</td>
<td>484.96 ± 137.20</td>
<td>204.27 ± 15.89</td>
<td>242.38 ± 30.04a</td>
<td>306.35 ± 28.09</td>
<td></td>
</tr>
<tr>
<td>Bone O.S/Bs (%)</td>
<td>2.92 ± 0.74</td>
<td>6.70 ± 2.16</td>
<td>22.02 ± 6.22</td>
<td>13.53 ± 2.42</td>
<td>10.97 ± 2.52</td>
<td>23.36 ± 6.22</td>
<td></td>
</tr>
<tr>
<td>Bone N.Ob/B.Pm (no/100mm)</td>
<td>1.13 ± 0.14</td>
<td>2.05 ± 0.27</td>
<td>2.94 ± 0.27</td>
<td>2.26 ± 0.18</td>
<td>2.47 ± 0.33</td>
<td>2.29 ± 0.36</td>
<td></td>
</tr>
</tbody>
</table>

Histomorphometry was performed in trabecular bone of the distal femur. BV/TV—Bone volume/tissue volume; Tb.Th—Trabecular thickness; Tb.Sp—Trabecular separation; OV/BV—Osteoid volume/bone volume; O.S/B—Osteoid surface/bone surface; O.Th—Osteoid thickness; Ob.S/Bs—Osteoblast surface/bone surface; N.Ob/B.Pm—Osteoblast number/bone perimeter; MAR—Mineral apposition rate; BFR/BS—Bone formation rate/bone surface; MS/BS—Mineralizing surface/bone surface; Et—Early phase; Ex—Late phase; N.Ob/B.Pm—Osteoblast number/bone perimeter; MAR—Mineral apposition rate; MS/BS—Mineralizing surface/bone surface; Et—Early phase; Ex—Late phase; N.Ob/B.Pm—Osteoblast number/bone perimeter; MAR—Mineral apposition rate; BFR/BS—Bone formation rate/bone surface; Mlt—Mineralization lag time. Values shown are mean±S.E.M.

†p<0.05 vs. age-matched control
of age, osteoblasts in male ΔGHR mice at six weeks of age appeared to perform more poorly than in control animals, as indicated by a significantly reduced bone formation rate per osteoblast (Figure 5C). Unfortunately, this dynamic histomorphometric measurement cannot be performed in 16-week-old mice to directly assess osteoblast activity at this age. Together, these in vivo data suggest that, although much of GH action in promoting skeletal development would appear to result from stimulating IGF-1 production, the GHR plays a distinct role in establishing the sexual dimorphism observed in the skeleton of adult mice.

**Discussion**

In this study, we used a genetic approach to disrupt the GHR in an osteoblast-restricted manner, enabling us to distinguish the contribution of GHR mediated signals to osteoblast function. The loss of GHR in osteoblasts in vitro diminished both the proliferative and anti-apoptotic effects of IGF-1 and impaired modestly osteoblast differentiation. Interestingly, osteoblasts lacking GHR had normal levels of IGF-1R protein but demonstrated reduced IGF-1-induced ERK and Akt phosphorylation. This result suggests that the presence of the GHR protein
resulting from a dramatic increase in bone formation despite the reduction in osteoblast number, likely osteoblasts however, three-week-development. Unlike female mice lacking IGF-1R in GH/IGF-1 in regulating osteoblast numbers in early development. The alterations described above in female ΔGHR mice suggest significant overlap in GH and IGF-1 function in osteoblasts. Namely, GH appears to stimulate local IGF-1 production from osteoblasts in control animals. In support of this notion, three-week-old, female transgenic mice in which IGF-1 was over-expressed specifically in osteoblasts had increased trabecular bone volume and dramatically increased measures of bone formation, with no change in the number of osteoblasts (30). By six weeks of age, female ΔGHR mice had nearly twice the number of osteoblasts compared to control animals and increased mineralization lag time; a histological picture, again, analogous to that previously observed in ΔIGF-1R mice (31). It appears likely that the increased numbers of osteoblasts in both mutants represent compensation by other growth factors in response to loss of GH/IGF-1 action. The inability to maintain normal bone volume later in life, despite the increase in osteoblast numbers, may relate to the reduced differentiation capacity observed in osteoblasts lacking the GHR in vitro. In addition, this deficiency in bone volume could owe to other components of the GH/IGF-1 system, namely, IGF binding proteins (IGFBP). For example, IGFBP5 levels increased dramatically at three weeks of age in the IGF-1 over-expressing mice mentioned above, coincident with the increase in osteoblast function (45). However, IGFBP5 levels decreased by six weeks of age, in both wild type and transgenic mice, when osteoblast activity had returned to normal in the IGF-1 over-expressing mice; presenting the possibility that reduced matrix-bound IGFBP5 might diminish the capacity of IGF-1 to stimulate bone formation in older animals (45), since matrix-bound IGFBP5 has been shown to potentiate IGF signaling (46, 47).

The changes observed in skeletal phenotype following loss of the GHR in vivo suggest both distinct and overlapping roles for GH and IGF-1 in postnatal bone acquisition. The histomorphometric changes observed in trabecular bone in female ΔGHR mice closely resembled those described previously in female mice lacking the IGF-1R in osteoblasts (31). For example, both female ΔGHR and ΔIGF-1R mutants demonstrated reduced trabecular osteoblast numbers at three weeks of age. These findings are compatible with the current in vitro observations of abolished GH-induced, and subsequent blunting of IGF-1-induced, proliferative/anti-apoptotic actions, demonstrating the importance of GH/IGF-1 in regulating osteoblast numbers in early development. Unlike female mice lacking IGF-1R in osteoblasts however, three-week-old female ΔGHR mice did not have lower bone volume compared to control animals. By contrast, female ΔGHR mice actually had increased trabecular bone volume at this age despite the reduction in osteoblast numbers, likely resulting from a dramatic increase in bone formation rate per osteoblast (12.47±6.12 vs. 2.02±1.23 mm²/Ob/yin controls). The increase in trabecular bone volume, despite reduced osteoblast numbers at three weeks of age in female ΔGHR mice, suggests that up-regulation of local IGF-1 via mechanisms other than GH might be able to compensate for the lack of GH-induced IGF-1 production from osteoblasts in control animals. In support of this notion, three-week-old, female transgenic mice in which IGF-1 was over-expressed specifically in osteoblasts had increased trabecular bone volume and dramatically increased measures of bone formation, with no change in the number of osteoblasts (30).
arise from precursors distinct from osteoblasts in the trabecular compartment, and evidence suggests these cells may have a differential response to PTH and estrogen (49). In addition, numerous studies, in both humans and animal models, have demonstrated that estrogen is predominantly responsible for periosteal expansion in males, converted from androgens by aromatase (50). In this regard, aromatase expression in bone is regulated by a promoter responsive to class I cytokines (51), and the GHR is class I cytokine receptor (52). Thus, it is an intriguing possibility, currently under investigation, that the failure of periosteal expansion observed in male ΔGHR mice might result from a reduction of GH-stimulated aromatase expression, and thus, ironically, the resultant lack of converted estrogen that would normally stimulate periosteal expansion produces a more “feminine” bone in male ΔGHR mice, while estrogen-replete females remain unaffected.

In summary, our studies demonstrate that the GHR is required for normal postnatal bone development in both sexes. As may be expected, GH appears to serve a primary function in modulating local IGF-1 action. However, osteoblast-restricted disruption of the GHR in male mice resulted in “feminization” of bone geometry in adult animals, suggesting GH may function to a greater extent than previously appreciated in establishing the sexual dimorphism of the skeleton.

Acknowledgements

The authors thank Drs. Yong Fan and Mark Sperling for providing the GHR® mice. This work was supported by grants from the NIH: R01 AR052746 to TLC and R01 AR062074 to DJD.

References

Osteoblast-restricted disruption of growth hormone receptor


